Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity. Issue 2 (10th August 2015)

• Record Type: Journal Article
• Authors: Bamodu, Oluwaseun Adebayo; Huang, Wen-Chien; Tzeng, David T.W.; Wu, Alexander; Wang, Liang Shun; Yeh, Chi-Tai; Chao, Tsu-Yi
• Is Part Of: Cancer letters. Volume 364:Issue 2(2015)
• Page Start: 125
• Page End: 134
• Publication Date: 2015-08-10
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.05.006
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">Ovatodiolide sensitizes triple negative breast cancer cells to doxorubicin anticancer activity.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">Sensitization of TNBC cells with Ovatodiolide before Doxorubicin treatment significantly suppresses their metastatic potential <italic>in vitro</italic>.</p> </list-item> <list-item id="u0020"> <label></label> <p id="p0020">Pre-treatment with Ovatodiolide before administration of Doxorubicin eliminates TNBC stem cell-like phenotype.</p> </list-item> <list-item id="u0025"> <label></label> <p id="p0025">Ovatodiolide-Doxorubicin sequential administration reduces doxorubicin-associated toxicity in non-tumorigenic cells.</p> </list-item> </list> </p> </sec> </abstract>